Dateline City:
WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.
Phase III clinical study data presented at IDWeek in Philadelphia
WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and
NYSE:SNY), announced today that the Biologics License Application (BLA)
filed for the companies investigational pediatric hexavalent vaccine,
DTaP5-IPV-Hib-HepB1, has been accepted for review
by the U.S. Food and Drug Administration (FDA).
Language:
English
Contact:
MerckMedia:Deb Wambold, (215) 652-2913orInvestors:Justin Holko, (908) 423-5088orSanofi PasteurMedia:Susan Watkins, (570) 957-2563susan.watkins@sanofipasteur.comorInvestors:George Grofik, (908) 981-5560IR@sanofi.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: SAN Exchange: BOURSE
Ticker: SNY Exchange: NYSE
read more